DSC127 is a patented analog of a naturally occurring peptide, Angiotensin. In multiple pre-clinical animal models, it has been shown to increase keratinocyte proliferation, increase extracellular matrix production, and increase vascularization. Additionally, histological examination has shown that DSC127 accelerated collagen deposition six-fold. All these help to accelerate dermal tissue repair. The drug is currently in Phase III of development for Diabetic Foot Ulcers treatment.